RVTY Quote, Financials, Valuation and Earnings

Avantor, Inc. has a net margin of 12.41% compared to Revvity, Inc.'s net margin of 3.15%. Revvity, Inc.'s return on equity of 3.2% beat Avantor, Inc.'s return on equity of -8.99%.

Revvity, Inc. has a consensus price target of $119.56, signalling upside risk potential of 19.67%. On the other hand Avantor, Inc. has an analysts' consensus of $11.04 which suggests that it could grow by 22.21%. Given that Avantor, Inc. has higher upside potential than Revvity, Inc., analysts believe Avantor, Inc. is more attractive than Revvity, Inc..

Revvity, Inc. has a beta of 1.066, which suggesting that the stock is 6.609% more volatile than S&P 500. In comparison Avantor, Inc. has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.874%.

Revvity, Inc. has a quarterly dividend of $0.07 per share corresponding to a yield of 0.28%. Avantor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revvity, Inc. pays 13.61% of its earnings as a dividend. Avantor, Inc. pays out -- of its earnings as a dividend. Revvity, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revvity, Inc. quarterly revenues are $772.1M, which are smaller than Avantor, Inc. quarterly revenues of $1.7B. Revvity, Inc.'s net income of $95.8M is higher than Avantor, Inc.'s net income of $52.4M. Notably, Revvity, Inc.'s price-to-earnings ratio is 48.37x while Avantor, Inc.'s PE ratio is 10.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revvity, Inc. is 4.08x versus 0.94x for Avantor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Azenta, Inc. has a net margin of 12.41% compared to Revvity, Inc.'s net margin of -3.49%. Revvity, Inc.'s return on equity of 3.2% beat Azenta, Inc.'s return on equity of 1.7%.

Revvity, Inc. has a consensus price target of $119.56, signalling upside risk potential of 19.67%. On the other hand Azenta, Inc. has an analysts' consensus of $38.67 which suggests that it could grow by 32.06%. Given that Azenta, Inc. has higher upside potential than Revvity, Inc., analysts believe Azenta, Inc. is more attractive than Revvity, Inc..

Revvity, Inc. has a beta of 1.066, which suggesting that the stock is 6.609% more volatile than S&P 500. In comparison Azenta, Inc. has a beta of 1.349, suggesting its more volatile than the S&P 500 by 34.927%.

Revvity, Inc. has a quarterly dividend of $0.07 per share corresponding to a yield of 0.28%. Azenta, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revvity, Inc. pays 13.61% of its earnings as a dividend. Azenta, Inc. pays out -- of its earnings as a dividend. Revvity, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revvity, Inc. quarterly revenues are $772.1M, which are larger than Azenta, Inc. quarterly revenues of $148.6M. Revvity, Inc.'s net income of $95.8M is higher than Azenta, Inc.'s net income of -$5.2M. Notably, Revvity, Inc.'s price-to-earnings ratio is 48.37x while Azenta, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revvity, Inc. is 4.08x versus 2.26x for Azenta, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bio-Rad Laboratories, Inc. has a net margin of 12.41% compared to Revvity, Inc.'s net margin of -52.36%. Revvity, Inc.'s return on equity of 3.2% beat Bio-Rad Laboratories, Inc.'s return on equity of 10.99%.

Revvity, Inc. has a consensus price target of $119.56, signalling upside risk potential of 19.67%. On the other hand Bio-Rad Laboratories, Inc. has an analysts' consensus of $324.00 which suggests that it could grow by 19.43%. Given that Revvity, Inc. has higher upside potential than Bio-Rad Laboratories, Inc., analysts believe Revvity, Inc. is more attractive than Bio-Rad Laboratories, Inc..

Revvity, Inc. has a beta of 1.066, which suggesting that the stock is 6.609% more volatile than S&P 500. In comparison Bio-Rad Laboratories, Inc. has a beta of 1.180, suggesting its more volatile than the S&P 500 by 18.018%.

Revvity, Inc. has a quarterly dividend of $0.07 per share corresponding to a yield of 0.28%. Bio-Rad Laboratories, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revvity, Inc. pays 13.61% of its earnings as a dividend. Bio-Rad Laboratories, Inc. pays out -- of its earnings as a dividend. Revvity, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revvity, Inc. quarterly revenues are $772.1M, which are larger than Bio-Rad Laboratories, Inc. quarterly revenues of $693.2M. Revvity, Inc.'s net income of $95.8M is lower than Bio-Rad Laboratories, Inc.'s net income of $720M. Notably, Revvity, Inc.'s price-to-earnings ratio is 48.37x while Bio-Rad Laboratories, Inc.'s PE ratio is 9.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revvity, Inc. is 4.08x versus 2.87x for Bio-Rad Laboratories, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bruker Corp. has a net margin of 12.41% compared to Revvity, Inc.'s net margin of 2.99%. Revvity, Inc.'s return on equity of 3.2% beat Bruker Corp.'s return on equity of -0.39%.

Revvity, Inc. has a consensus price target of $119.56, signalling upside risk potential of 19.67%. On the other hand Bruker Corp. has an analysts' consensus of $48.43 which suggests that it could grow by 26.51%. Given that Bruker Corp. has higher upside potential than Revvity, Inc., analysts believe Bruker Corp. is more attractive than Revvity, Inc..

Revvity, Inc. has a beta of 1.066, which suggesting that the stock is 6.609% more volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.186, suggesting its more volatile than the S&P 500 by 18.621%.

Revvity, Inc. has a quarterly dividend of $0.07 per share corresponding to a yield of 0.28%. Bruker Corp. offers a yield of 0.52% to investors and pays a quarterly dividend of $0.05 per share. Revvity, Inc. pays 13.61% of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Revvity, Inc. quarterly revenues are $772.1M, which are smaller than Bruker Corp. quarterly revenues of $977.2M. Revvity, Inc.'s net income of $95.8M is higher than Bruker Corp.'s net income of $29.2M. Notably, Revvity, Inc.'s price-to-earnings ratio is 48.37x while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revvity, Inc. is 4.08x versus 1.69x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.